Weekly Ratings, Targets, Forecast Changes – 20-11-26

Weekly Reports | 10:00 AM

Weekly update on stockbroker recommendation, target price, and earnings forecast changes.

By Mark Woodruff

Guide:

The FNArena database tabulates the views of seven major Australian and international stockbrokers: Citi, Bell Potter, Macquarie, Morgan Stanley, Morgans, Ord Minnett, and UBS.

For the purpose of broker rating correlation, Outperform and Overweight ratings are grouped as Buy, Neutral is grouped with Hold and Underperform and Underweight are grouped as Sell to provide a Buy/Hold/Sell (B/H/S) ratio.

Ratings, consensus target price and forecast earnings tables are published at the bottom of this report.

Summary

Period: Monday November 16 to Friday November 20, 2026
Total Upgrades: 7
Total Downgrades: 21
Net Ratings Breakdown: Buy 64.30%; Hold 28.85%; Sell 6.85%

For the week ended Friday, 20 November 2026, the seven stockbrokers monitored daily by FNArena issued seven ratings upgrades and 21 downgrades for ASX-listed companies.

a2 Milk Co, global investment management firm GQG Partners and TechnologyOne each attracted two downgrades.

While a2 Milk reaffirmed FY27 guidance, Ord Minnett expects weaker Chinese infant formula demand to slightly reduce first-half revenue, increasing reliance on the second half (as per management's indication).

Citi noted China-label offtake recovered to around 50% of pre-disruption levels from 40%, but regaining customers requires further marketing investment.

GQG Partners' deteriorating fund flows and investment performance concerned brokers. Morgans highlighted October net outflows of -US$6.7bn and investment losses of -US$11bn, reducing funds under management by -12% to US$131.6bn.

Ord Minnett lowered its target to 80c from $1.90, reflecting earnings downgrades and more conservative valuation assumptions. Both Ord Minnett and Morgans highlighted the attractive dividend yield, although Morgans flagged ongoing earnings risks.

TechnologyOne's robust though in-line FY26 results challenged the artificial intelligence (AI) disruption narrative, with its AI-Plus product outperforming.

Further details are available in FNArena’s Corporate Results Monitor: https://fnarena.com/2026/11/20/fnarena-corporate-results-monitor-20-11-2026/

For a more thorough analysis of analysts' assessments: https://fnarena.com/2026/11/19/technologyone-ais-trojan-horse-flywheel/

The week's tables below show percentage declines in average target prices outnumbering increases, while earnings forecast upgrades exceeded downgrades for the first time in five weeks.

AI-powered cardiovascular medical technology company Artrya ranked second behind TechnologyOne for positive target changes, while EchoIQ, also an AI-powered cardiovascular medical technology company, ranked second behind GQG Partners for negative revisions.

Artrya secured a five-year agreement with HonourHealth, a nine-hospital Arizona network, providing minimum fees of US$0.5m plus per-scan revenue, subject to FDA approval.

Bell Potter noted HonourHealth becomes Artrya's fifth and second-largest customer, with plans for a cardiovascular imaging centre of excellence supporting US expansion.

Morgans views Artrya as a multi-year growth opportunity, with customer acquisition and scan utilisation more important than near-term revenue.

The latter broker noted revenue is now recognised when scans are completed rather than payments received, following a change in accounting.

EchoIQ's US FDA appeal for its EchoSolv heart failure product was unsuccessful.

Ord Minnett considered the initial -42% share price reaction excessive. This broker sees upside despite regulatory uncertainty, with a new submission potentially decided in late 2027.

Alternative investment and asset managers Regal Partners and MA Financial recorded target price declines of -11% and -10%, respectively, partly reflecting inaugural broker coverage.

Macquarie commenced MA Financial coverage with a $5.10 target and Neutral rating, highlighting private credit outflow risks and earnings pressure across three divisions.

Macquarie expects Finsure's mortgage aggregation market share gains to offset weaker conditions, while subdued corporate advisory activity remains a drag. Its FY27 earnings per share (EPS) forecast is -13% below consensus.

For Regal, Macquarie initiated with a $3.65 target and Outperform rating, forecasting annual net inflow growth of 6%–12% across FY26–FY28.

The initiation report suggests concerns surrounding co-founder Philip King's retirement and overall private credit exposure are excessive, highlighting a 6.8x forward earnings multiple and 21% annual forecast EPS growth.

Separately, price targets were also negatively impacted after management provided a fund performance, fee revenue and other income update on November 12.

The asset manager expects at least $122.7m in 2026 performance fees following hedge fund losses, -$74m below Morgans' forecast.

Regal also ranked second for the week's declines in earnings forecasts, behind Catapult Sports.

Higher-than-expected acquisition costs, primarily associated with recently acquired sports technology company Impect, contributed to a wider statutory net loss of -US$19.1m, triggering a -17% share price fall that UBS considered excessive. See the Results Montor for more views.

Bellevue Gold received a -22% consensus earnings forecast cut.

Ord Minnett welcomed its $250m refinancing and planned December-quarter hedge closure, providing full exposure to spot gold prices.

The broker lowered its FY27 EPS forecast by -63.6% for hedge closure costs but raised FY28 by 72.7%.

Positive free cash flow (FCF) is now expected this quarter, rather than mid-to-late 2027.

Lendlease and Transurban followed with respective consensus earnings forecast declines of -20% and -11%.

Morgan Stanley lowered Lendlease's target to $2.24 from $3.21 and downgraded to Underweight from Equal-weight, citing delayed asset sales and increased balance sheet risks.

The broker questioned Lendlease's ability to achieve its 5%–15% gearing target without selling assets below book value, with $2.4bn awaiting disposal.

Potential losses of up to -$8bn in funds under management added to concerns.

Citi lowered Transurban's target to $13.90 from $14.70 and downgraded to Sell from Neutral following October traffic growth of just 0.7%.

The broker attributed weakness to higher fuel costs and household pressures, contrasting subdued Australian volumes with 13% North American growth.

Macquarie expects subdued Australian bond yields to support Transurban's valuation, while its established US presence offers attractive growth opportunities.

Turning to positive revisions to earnings forecasts, Minerals 260 leads Nufarm at the top of the week's Top 10 table.

Ord Minnett welcomed Minerals 260's $410m Bullabulling gold project funding, secured at interest rates -150bps below expectations, with interest capitalised during construction.

The broker lowered its weighted average cost of capital assumption to 8% from 10%, lifting its target to $1.60 from $1.35.

A definitive feasibility study (DFS) and final investment decision (FID) are expected in 1Q27, ahead of first production in late 2028.

Ord Minnett downgraded to Speculative Buy from Buy, citing execution risks.

Nufarm and Elders joined the earnings upgrade table following respective in-line and better-than-expected results, after GrainCorp's upbeat margin commentary the previous week.

See https://fnarena.com/2026/11/17/moving-parts-to-drive-elders/ for more detail on Elders.

Wildcat Resources' higher target and lower earnings forecasts reflected UBS initiating coverage with a 50c target and Buy rating.

UBS sees potential for Tabba Tabba to become Australia's sixth-largest lithium mine, producing over 600,000t of spodumene concentrate annually.

Computershare's consensus earnings forecast rose 11% following its 12 November AGM.

UBS highlighted a stronger-than-expected FY27 start and upgraded margin income guidance of US$805m from US$770m. FY27 EPS guidance remained US154c, up 5% year-on-year.

Elsewhere, Aristocrat Leisure enjoyed upgrades to target prices following November 12’s FY26 results: https://fnarena.com/2026/11/18/aristocrats-winning-hand-and-a-new-ceo/

Buy ratings now represent 64.30% of FNArena's database, down from 65.04% previously. Neutral/Hold ratings account for 28.85% and Sell ratings 6.85%.

Upgrade

INFRATIL LIMITED ((IFT)) Upgrade to Buy from Accumulate by Morgans .B/H/S: 5/0/0

Infratil's 1H27 result exceeded Morgans' expectations, with proportional EBITDA rising 30% y/y, 9% ahead of forecasts.

Post-fee NAV increased 15% y/y to NZ$17.94 per share. Following recent share price weakness, the broker upgrades its rating to Buy from Accumulate, retaining a target price of A$13.80.

FY27 operational EBITDA guidance was raised to NZ$1,370m–NZ$1,440m, supported by stronger contributions from CDC and One NZ. CDC's EBITDA guidance increased to $730m–$770m, while Qscan's was lowered to $75m–$85m.

CDC now accounts for 51% of portfolio NAV, supported by a NZ$2.4bn valuation uplift, although higher bond yields remain a headwind for long-duration assets. Infratil faces substantial investment requirements, with around -NZ$2bn in proportional capex expected in 2H27.

LYNAS RARE EARTHS LIMITED ((LYC)) Upgrade to Accumulate from Hold by Ord Minnett .B/H/S: 4/0/1

Ord Minnett upgrades Lynas Rare Earths to Accumulate from Hold with a slightly lower target price of $13 from $13.50.

The analyst notes Lynas faces a slower NdPr production ramp-up as customers increasingly require dysprosium and terbium alongside NdPr.

Sales growth assumptions and realised price forecasts are lowered, noting some NdPr sales are achieving less than US$110/kg and DyTb pricing is below Serra Verde offtake levels.

Lynas is viewed as more fairly valued following recent share price weakness, but commentary points out the anticipated Mt Weld cutback could involve substantial capex without immediate revenue benefits, while investors await the appointment of a new CEO and further details on the Caldeira project.

NEW HOPE CORPORATION LIMITED ((NHC)) Upgrade to Hold from Sell by Bell Potter .B/H/S: 3/1/0

Bell Potter lowers its target for New Hope to $4.80 from $5.30 but upgrades to Hold from Sell following share price weakness and new FY27 production guidance.

The company reported quarterly saleable production of 2.9Mt, down -6% quarter-on-quarter, and sales of 2.9Mt, down -3%. Both missed the analysts' 3.0Mt forecasts.

Guidance suggests production will rise 6% to 11.5Mt–13Mt, supported by New Acland's expansion.

New Hope is raising $250m through hybrid notes ahead of its proposed Malabar acquisition, potentially reducing financing costs.

FY27 EPS forecasts are lowered by -27%, while FY28 and FY29 forecasts rise by 1% and 4%, respectively.


The full story is for FNArena subscribers only. To read the full story plus enjoy a free two-week trial to our service SIGN UP HERE

If you already had your free trial, why not join as a paying subscriber? CLICK HERE

MEMBER LOGIN

Australian investors stay informed with FNArena – your trusted source for Australian financial news. We deliver expert analysis, daily updates on the ASX and commodity markets, and deep insights into companies on the ASX200 and ASX300, and beyond. Whether you're seeking a reliable financial newsletter or comprehensive finance news and detailed insights, FNArena offers unmatched coverage of the stock market news that matters. As a leading financial online newspaper, we help you stay ahead in the fast-moving world of Australian finance news.